IE Ulagay-Menarini Group has a wide range of product portfolio, which concentrates on antibacterial, antihypertensive and Pain & anti-inflammation areas.
IE Ulagay-Menarini Group has been one of the leading antibiotic companies in the market. IE Ulagay-Menarini Group’s assiduous commitment to the antibiotic area has remained constant; as a result, today IE Ulagay-Menarini Group is providing to Turkish doctors a wide range of antibacterial products which are oral and injectable forms of penicinlins, macrolides, fluoroquinolones, cephalosporines and aminoglicosides.
After the Menarini merge in 2001, IE Ulagay-Menarini Group has begun the registration process of innovative drugs in following areas;
Antihypertensive
Gastro-enterology
Pain & anti-inflammation
Anti-Migraine
Anti-Viral
In the last seven years IE Ulagay-Menarini Group has provided the Turkish doctors three new anti-hypertensives, one oral NSAID, one topical NSAID, one anti-spasmolitic, one anti-migraine and one anti-viral innovative product.
IE Ulagay-Menarini Group's contribution to the cardiovascular area goes back to 2003. Particularly in the cardiovascular sector, IE Ulagay-Menarini Group has concentrated on the area of the prevention of risk factors, treatment of hypertension being paramount.
The first introduction to the cardiovascular area was a new generation beta blocking agent, Vasoxen (Nebivolol) has been launched in 2003.
In the following years, IE Ulagay-Menarini Group continued to provide new innovative therapy alternatives to the market, plain Ace Inhibitors Zoprotec (Zofenopril) has been introduced to market in 2004 and the plain ARB Antagonist Hipersar (Olmesartan Medoxomil) has been launched in 2005.
Today, IE Ulagay-Menarini Group is the fastest growing pharmaceutical company in cardiovascular area since 2003 with a significantly enlarging product portfolio. These successful results are backed up by an updated scientific information service which is through and capillary on the all national land.
For several years, now IE Ulagay-Menarini Group has been actively engaged in the fight against painful symptomatologies by the means of intense research and development of new active principles carried out by Menarini researchers in the most advanced subject areas in Turkey.
Another important product Zostex (Brivudin) has been launched as a new anti-viral agent in 2003. This product is an alternative for the treatment of Herpes Zoster.
In the beginning of 2007, IE Ulagay-Menarini Group launched Migrex ( Frovatriptan ) as a new molecule for the treatment of the Migraine symptoms.
Zopretec Plus 30/12.5 mg Film Coated Tablet containing Zofenopril which is a ACE inhibitor and Hydrochlorothiazide which is a diuretic and Hipersar Plus 20/12.5 mg-20/25 mg Film Coated Tablet containing Olmesartan Medoxomil which is a ARB inhibitor and Hydrochlorothiazide which is a diuretic have been presented to the service of Turkish Health Sector.
Also, The ampoule form of Arveles Tablet (Arveles 50mg/2 mL IM/IV 6 Ampoule) was introduced to the Turkish Market at the end of 2008.
IE Ulagay-Menarini Group’s main objective is to continue providing innovative therapy alternatives to the Turkish health sector in the near future.
